β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. - sprookjes - yvandenbroek - TriplyDB

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.

http://www.wikidata.org/entity/Q33758547

about

Are beta blockers still necessary for all survivors of acute myocardial infarction?Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?The role of beta-blockers in the management of chronic obstructive pulmonary disease.β-Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In-Hospital and 12-Month Outcome: Results From the GULF-RACE 2 (Gulf Registry of Acute Coronary Events-2).Heart-breaking aspirin interruption.Effect of β-Blockers Beyond 3 Years After Acute Myocardial Infarction.Current Indications for Stenting: Symptoms or Survival CME.Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

P2860

Q47131804-88014E9C-151F-4A26-BAE5-B98DCAD18F6C Q47138444-AC795B7D-A4B5-4056-865E-6C723AD05257 Q47676572-E7A1DD34-B698-4F81-8F90-2270006ADFCF Q49234909-B2E2AD34-7C35-4548-97BE-9D7C92F12911 Q52806304-677EB4CF-0555-4632-B4FB-4C97A5A0F490 Q53080727-0D2B9257-9F16-42A8-BFB4-DA139F031608 Q55315249-CED02AD7-14F3-4689-9B0D-E31B4A3ECBAF Q58699927-E2C04F90-FBC9-4859-93F5-0D89299A0845

P2860

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.

http://www.wikidata.org/entity/Q33758547

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@ast

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en-gb

type

label

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@ast

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en-gb

prefLabel

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@ast

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en

β-Blockers and Mortality After ...... re or Ventricular Dysfunction.

@en-gb

P1154

Q33758547-54C952A5-513E-4FDC-A170-F61B24DDB6CB

P1433

Q33758547-ADE8A354-8B46-4181-ABB1-A1D01AA3066D

P1476

Q33758547-1649F22A-E109-4468-80E0-9DA1CAE739BD

P2093

Q33758547-0B779474-A801-40DB-82DD-F6984CBE52AF

Q33758547-2A698F6B-CDE7-44E9-B763-72127A0F00F4

Q33758547-3999E358-1C4F-435C-B8AB-6BDBB49E3006

Q33758547-4F1DF795-6B01-485E-8898-23185A189BF8

Q33758547-79109947-F6BD-465E-966D-FFB8893E46B5

Q33758547-CBADAE7C-8C6D-4CF6-9657-D87D89D1983A

Q33758547-D82EF54A-1BC8-477D-AD38-1E414FA0AE47

P2860

Q33758547-2C54A950-137E-4F12-8766-10D6A37FC5D0

Q33758547-2EA95AB4-0ABA-4A0A-8B58-87B3E85FF8AB

Q33758547-3F951491-236B-4EA4-83C2-112842D16C97

Q33758547-51A00A64-FF6A-41C0-8127-9905CE26F675

Q33758547-63D9323B-D495-4659-9CC2-69EA2457AF6A

Q33758547-6C21A707-2837-4186-AD87-C684B3F979B1

Q33758547-7F940461-6F68-4B98-8FF3-16685EC35146

Q33758547-87B5A377-439F-4802-96F9-6056A073C3FA

Q33758547-92656A83-3916-4B25-86D2-BA48578C331F

Q33758547-9B3B5EF7-209B-4A36-9950-81668BE47613

P304

Q33758547-D55D7A0E-4CA1-470B-B89A-35AFEAD93CA7

P31

Q33758547-BE9AF83B-C8DF-40DE-A179-DBF8FABA9F42

P356

Q33758547-87EA64F0-9510-43AD-B99E-645C5F38BC07

P407

Q33758547-7EE72946-8FC0-4188-94E0-3A9986FC24EA

P433

Q33758547-B1A8244C-2D16-4BE2-BAE2-36DA413EA6F4

P478

Q33758547-DF795E57-B2DF-491D-8F2C-174C764842EF

P50

Q33758547-47A67443-0B6D-4978-8BE6-ED78C63E1CBB

Q33758547-8C33BE01-1F26-4EDB-BA2C-57D6D4CFC9F9

Q33758547-C28A8610-2D3F-43EC-8AB4-F61C90F42335

Q33758547-D63F0F65-EFFA-4867-AE18-7BE7654CD7DA

Q33758547-F4248B85-C4D9-4B6C-B980-222B417BB3ED

P5530

Q33758547-EF81DF52-BAD7-4E2D-B086-EAF5B814D806

P577

Q33758547-F4DF8A00-B7B9-4FAF-88B6-964EB7CD803F

P6179

Q33758547-D0755177-C820-47FE-B999-9CD42E1D0921

P6409

Q33758547-5F82E155-D0BE-42B6-9233-09C957EAEC3A

P698

Q33758547-76946837-29FF-4308-940C-CA6E38C05BAA

P921

Q33758547-D4F4A57A-B7AF-45E3-85BC-DF4B56CA72DD

P932

Q33758547-5AED469D-90E4-4893-B299-178EF186F105

P953

Q33758547-C266C5DF-23B0-4B9C-8D9D-FDB0E5E84AB8

P356

J.JACC.2017.03.578

P1154

2-s2.0-85019696725

http://www.w3.org/2001/XMLSchema#string

P1433

Journal of the American College of Cardiology

P1476

β-Blockers and Mortality After ...... ure or Ventricular Dysfunction

@en

P2093

Adam D Timmis

http://www.w3.org/2001/XMLSchema#string

Bertil Lindahl

http://www.w3.org/2001/XMLSchema#string

Chris P Gale

http://www.w3.org/2001/XMLSchema#string

Harry Hemingway

http://www.w3.org/2001/XMLSchema#string

Nicolas Danchin

http://www.w3.org/2001/XMLSchema#string

Robert M West

http://www.w3.org/2001/XMLSchema#string

Tomas Jernberg

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

The Myocardial Ischaemia National Audit Project (MINAP).

P304

2710-2720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2017.03.578

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Marlous van Laar

Tatendashe B Dondo

P5530

20687101

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085713479

http://www.w3.org/2001/XMLSchema#string

P6409

87668843

http://www.w3.org/2001/XMLSchema#string

P698

28571635

http://www.w3.org/2001/XMLSchema#string

P921

P932

5457288

http://www.w3.org/2001/XMLSchema#string

P953